Prolong Pharmaceuticals
South Plainfield, New Jersey, United States
About Prolong Pharmaceuticals
Prolong Pharmaceuticals, Inc. develops and markets biopharmaceutical products. Its products include PEG-uricase for the treatment of hyperuricemia; PEG-arginase for the treatment of melanoma and hepatocellular carcinoma; PEG-protein for the treatment of hypovolemic shock; PEG-peptide antibiotic to treat staphylococcus infections; PEG-streptokinase for myocardial infarcts; anti-cancer agents; and Erythropoietin, a biopharmaceutical that provides a solution for anemia. The company also offers custom manufacturing services; and licenses its products to pharmaceutical companies. Prolong Pharmaceuticals, Inc. was founded in 2002 and is based in New Jersey.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $30.0M
- Last round: Series Unknown (Oct 2010)
- Website: prolongpharma.com
- Phone: 908-444-4660
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/prolong-pharmaceuticals-2458202 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.